NeoStem 和 Progenitor Cell Therapy 宣布达成并购协议

 两家公司将形成一个综合性全球细胞疗法公司

艾伦代尔纽约和新泽西州2010年9月24日电 /美通社亚洲/ -- 在美国和中国经营业务的国际生物制药公司 NeoStem, Inc. (NYSE Amex: NBS)，和通过位于新泽西州和加利福尼亚州最先进的细胞疗法生产设施服务于细胞疗法行业的私人持有的细胞疗法公司 Progenitor Cell Therapy, LLC 今天联合宣布签署了一项最终合并协议，NeoStem 将收购 Progenitor Cell Therapy。最终合并协议规定 NeoStem 总计发行11,200,000股普通股并担保购买总计不低于1,000,000股，最多3,000,000 股的 NeoStem 普通股额外股份来交换 Progenitor Cell Therapy 所有成员的权益。

超过50%的 NeoStem 的普通股持有者和超过50%的 PCT 成员权益持有者已同意投票支持该合并。合并的完成受到各种条件制约，包括 NeoStem 的股东批准发行用于合并的 NeoStem 证券。

PCT 的创收业务将将增加 NeoStem 成长中的成人干细胞业务，并且 PCT 的管理层将把 PCT 管理团队在商业和细胞疗法科学和发展方面超过100年的集体经验带入 NeoStem 。自1999年成立以来，PCT 曾服务于世界各地100多家客户，并进行了超过20个不同的细胞疗法。PCT 已经在其细胞疗法生产设施完成超过30,000例细胞疗法程序，处理和储存超过18,000份细胞疗法产品（包括约7,000份脐带血、10,000份血液和骨髓干细胞和1000份树突状细胞），并安排了物流和运输超过14,000份细胞疗法产品用于超过5000名患者的临床使用。

NeoStem 首席执行官 Robin Smith 博士表示：“我们很高兴与 PCT 达成协议，并认为这次合并将有利于两家公司的股东。此次收购是 NeoStem 通过增加细胞疗法生产和储存设施以及增强新兴的细胞疗法产业受到监管的综合合规分销能力，努力发展‘一站式商店’细胞疗法全球网络核心竞争力的重大一步。PCT 的全球影响力和声誉将加快合并后的公司进入这个令人振奋的市场。”

合并完成以后，PCT 首席执行官 Andrew Pecora 博士将应邀加入 NeoStem 董事会，他表示：“我们很高兴在经历十年的辛勤工作以后，我们 PCT 团队可以通过与 NeoStem 组成开发多种成人干细胞能力的平台来为忠实的投资者带来投资回报。我们在 Dendreon Corporation 的自体细胞免疫药物 Provenge 的生产中发挥了重要作用，这种作用从临床实验一直延续到它获得美国食品与药品管理局 (FDA) 的批准，此时我们对把公司在细胞疗法开发市场上的竞争能力带给 NeoStem 感到特别高兴，这将有助于 NeoStem 的 VSEL(TM) 技术和其它未来细胞疗法产品向前发展。此外，新公司将拥有 NeoStem 的自体成人干细胞采集能力和 PCT 的脐带血采集及长期储存服务，它将成为同行中首家向家庭提供现有 cGMP（动态药品生产管理规范）自体干细胞采集和储存服务的企业。”

专注于生命科学行业的投资银行公司 LifeTech Capital 通过提供此次交易的估值分析来为 NeoStem 提供咨询服务，这家公司是 Aurora Capital 旗下的部门。

NeoStem 和 PCT 将在纽约的 NASDAQ MarketSite（纳斯达克 MarketSite 大厦）回答有关此次交易的问题。

时间：美国东部时间2010年9月23日下午1:00
地点：纽约时代广场 (Times Square) 4号（43街 (43rd) 和百老汇 (Broadway)）
回复方式：电话：917.680.6011；电邮：Bradley.smith@muncmedia.com

NeoStem, Inc. 简介

NeoStem 从事干细胞疗法开发业务，开展抗衰老计划，并力求打造一个美国和中国成人干细胞采集中心网络，致力于使人们能够捐赠和存储他们自己的（自体）干细胞，以供自身日后有医疗需求时使用。该公司还获得了各种干细胞技术的授权，包括利用极小胚胎样干细胞的 VSEL(TM) 技术的全球独家授权。研究显示，极小胚胎样干细胞具有一些通常在胚胎干细胞中发现的物理特性。此外，该公司正在寻求其它疗法用技术的授权。NeoStem 控股的中国制药业务苏州二叶制药有限公司在中国生产和销售抗生素仿制药。垂询详情，请访问：http://www.neostem.com 。

PCT 简介

PCT 通过在新泽西州 Allendale 和加州山景城获得许可证并利用最新先进技术的细胞疗法产品制造工厂来为包括生物科技、药品和医疗产品企业、医疗保健供应商和学术研究机构在内的细胞疗法行业的发展提供服务。该公司为那些专门旨在加快细胞疗法广泛应用的领先学术机构的研究提供支持。PCT 的核心战略是为不断向前发展的细胞疗法行业提供细胞疗法产品制造和储存设施全球网络与受到监管的综合合规分销能力，以便满足国际商业需求。垂询详情，请访问：http://www.progenitorcelltherapy.com 。

前瞻性声明

本新闻稿包含美国《1995年私人证券诉讼改革法》(Private Securities Litigation Reform Act of 1995) 所界定的前瞻性陈述。前瞻性陈述反映的是管理层截至本新闻稿发布之日的当前预期，并涉及某些风险和不确定因素。前瞻性陈述包括本文中有关与 Progenitor Cell Therapy, LLC 提议合并的陈述，对此不做任何担保。该公司的实际结果可能会由于各种因素的影响而与这些前瞻性陈述中的预期大相径庭。可能导致未来结果与近期结果或前瞻性陈述中预测的结果产生重大出入的因素包括该公司最近提交给美国证券交易委员会 (Securities and Exchange Commission) 的 10-K 表年度报告和定期提交给该委员会的其它文件中描述的“风险因素”。该公司今后的发展在很大程度上取决于未来医学与研究的发展以及市场认可度，这些并不在该公司的控制范围之内。

NeoStem, Inc.
首席执行官 Robin Smith
电话：+1-212-584-4174
电邮：rsmith@neostem.com
网址：http://www.neostem.com

消息来源 NeoStem, Inc.

 

NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy Sep 27 2010

NEW YORK -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, appeared on Thursday at the NASDAQ  MarketSite in Times Square in connection with its announcement of the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.  

The definitive merger agreement provides for the issuance of an aggregate of 11,200,000 shares of NeoStem common stock in exchange for all of Progenitor Cell Therapy membership interests. The bulk of these shares will be held in an escrow account for at least one year from closing and will not be available for sale.  Additional consideration includes warrants to purchase an aggregate of no less than 1,000,000 and a maximum of 3,000,000 additional shares of NeoStem common stock at $3, $5 and $7 exercise prices. Holders of greater than 50% of NeoStem's common stock and greater than 50% of PCT's membership interests have agreed to vote in favor of the merger.    

Dr. Smith discussed how this acquisition is a significant step in NeoStem's efforts to develop a "one-stop-shop" for global cell therapy and highlighted key considerations in the merging of the two companies, including:

• In 2009, PCT generated over $8,000,000 in revenue.  Its business will be accretive to NeoStem's growing adult stem cell operations and PCT has demonstrated that cellular therapy can be a revenue generating business.
• PCT's management will remain in place.  They bring over 100 years of collective experience in the business and science of cell therapy and its development.
• Since its inception in 1999, PCT has performed over 30,000  cell therapy procedures in its cell therapy manufacturing facilities and processed and stored over 18,000 cell therapy products (including umbilical cord blood units, blood and marrow derived stem cells and  dendritic cells).
• PCT has served over 100 clients from around the world and is experienced with more than 20 different cell based therapeutics.  Most exciting is the fact that over 5,000 patients have been treated  with the cell therapy products that have been logistically arranged and transported by PCT
• PCT has played an instrumental role in the manufacturing of  Provenge  throughout the clinical trial process,  that has led to Dendreon's successful FDA approval of the first major autologous cellular immunotherapy.  We believe PCT's core competencies in cell therapy development will contribute to moving forward NeoStem's proprietary VSEL ™ Technology.
• Additionally, between NeoStem's  autologous adult stem cell collection capabilities and PCT's umbilical cord blood collection and long term storage services, the combined company will be the first of its kind to provide families autologous stem cell collection and storage with current Good Manufacturing Practices (cGMP)".

The closing of the merger is subject to various conditions, including the approval by NeoStem's stockholders of the issuance of NeoStem's securities in the merger.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL^™ technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties, including whether the merger ultimately will be consummated. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 and the form 8k filed on Sept 23, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

For more information, please contact: